• No results found

Low BCL7A expression predicts poor prognosis in ovarian cancer

N/A
N/A
Protected

Academic year: 2020

Share "Low BCL7A expression predicts poor prognosis in ovarian cancer"

Copied!
7
0
0

Loading.... (view fulltext now)

Full text

Loading

Figure

Table 1 The baseline information of ovarian cancer patientsfrom TCGA database
Fig. 1 The different BCL7A expression levels shown in a boxplot. The differential expression of BCL7A in tumour vs normal tissues (groups according to stage (a) and otherb), histologic grade (c), new type (d), vital status (e), lymphatic invasion (f), subdivision (g) and age (h)
Fig. 2 Survival analysis of BCL7A expression in terms of overall survival. Kaplan–Meier curves produced survival analysis (a) and subgroup analysisof early stage (b), advanced stage (c), histological grade G1/G2 (d) and G3/G4 (e), lymphatic invasion (f), non-lymphatic invasion (g), youngpatients (h) and older patients (i)
Table 3 Univariate and Multivariate Cox analysis of overall survival in ovarian cancer
+2

References

Related documents

Since 1983, the term “Wizard of Oz” has come into common usage in the fields of Experimental Psychology, Human Factors, Ergonomics and Usability Engineering to describe a testing

Adhesive dispersion-type transdermal drug delivery system On the top of the drug reservoir layer, thin layers of non-medicated, rate controlling adhesive polymer of a specific

She said, “my darling do you know why you love to serve your religion, the community and humanity?” İbrahim was silent for a while and felt his aunt wanted to say an

The second clinical trial enrolled 48 eyes of 24 patients with stable refraction and moderate-to-high astigmatism to undergo PRK by the cross-cylinder method using a NIDEK

Immunohistochemistry analysis showed significant decrease of CaMKII in the CA1 region of 11 months old APPV717I transgenic mice (compare to control group p < 0.01), while the

Hormonal therapies are reserved not only for patients with biochemical markers of hyperandrogenism but also for the severe, resistant cases as well as for those patients who show an

Resolution on the neutron energy (right) and background level (left) for a proton therapy spectrum as a function of the distance between the diode and the third CMOS